sophi
trouilletass
phd
sebastien
viel
pharmd
phd
alexandr
gaymard
merazga
excel
work
thank
fabien
subtil
help
advic
statist
analysi
also
thank
life
lyon
immunopatholog
feder
commun
fruit
discuss
capsul
summari
covid
patient
icu
present
high
mortal
rate
immunoprofil
reveal
heterogen
product
criticallyil
patient
unabl
produc
highlight
immun
respons
heterogen
open
avenu
target
therapi
editor
sever
acut
respiratori
syndrom
coronaviru
infect
character
wide
spectrum
diseas
encompass
asymptomat
carriag
mild
sever
upper
respiratori
tract
ill
evolv
respiratori
failur
rapidli
progress
sever
viral
pneumonia
acut
respiratori
distress
syndrom
ard
diseas
sever
depend
viral
strain
host
risk
factor
identifi
age
male
gender
addit
excess
immun
respons
identifi
patient
show
cytokin
storm
associ
ard
variou
immunosuppress
drug
includ
blocker
jakstat
signal
inhibitor
suggest
treatment
infect
wherea
addit
clinic
trial
evalu
use
recombin
interferon
foster
host
antivir
respons
clinicaltri
type
interferon
ifni
major
compon
innat
immun
system
repres
critic
antivir
molecul
date
ifni
respons
evalu
patient
contribut
viral
control
inflamm
unknown
studi
assess
kinet
plasma
ifni
patient
spectrum
sever
degre
studi
approv
ethic
committe
biomed
research
de
protect
de
personn
hcl
supplement
materi
method
articl
onlin
repositori
firstli
explor
three
patient
issu
first
covid
cluster
diagnos
franc
le
contamin
haut
savoi
franc
februari
took
advantag
new
digit
elisa
technolog
singlemolecul
array
simoa
analyz
kinet
plasma
inflammatori
cytokin
interleukin
il
creactiv
protein
crp
interferon
protein
elev
two
symptomat
patient
supplementari
figur
onlin
repositori
strikingli
detect
two
patient
contrast
crp
elev
plasmat
observ
viral
load
low
obviou
quantit
differ
three
patient
explor
larger
cohort
critic
ill
covid
patient
one
intens
care
unit
icu
hospic
civil
de
lyon
lyon
franc
note
patient
treat
standard
care
none
receiv
antivir
immunotherapi
consid
first
day
infect
half
critic
ill
patient
requir
invas
mechan
ventil
observ
patient
demonstr
peak
day
symptom
onset
correspond
viral
replic
phase
decreas
overtim
low
still
detect
time
interferon
exposit
may
critic
control
viru
avoid
immunopathogenesi
channappavanar
et
al
shown
delay
ifni
express
detriment
mice
context
infect
data
suggest
screen
patient
ifn
product
instrument
select
could
benefit
earli
intervent
ifn
follow
day
remain
increas
taper
kinet
highlight
cytokin
inhibitor
could
help
second
phase
diseas
follow
ifni
decreas
viral
characterist
individu
genet
suscept
explor
understand
defect
product
covid
patient
posit
patient
also
experienc
fatal
outcom
highlight
multifactori
caus
diseas
sever
acknowledg
limit
studi
relat
small
number
includ
patient
technic
limit
measur
proof
concept
studi
provid
new
argu
earli
intervent
recombin
also
highlight
window
opportun
immunosuppressor
second
phase
diseas
delay
symptom
onset
icu
admiss
day
bacteri
coinfect
icu
stay
n
diabet
n
chronic
obstruct
pulmonari
diseas
n
cardiovascular
diseas
n
hypertens
n
cancer
n
activ
smoker
n
mortal
symptom
onset
n
crp
creactiv
protein
icu
intens
care
unit
bmi
bodi
mass
index
tabl
clinic
characterist
patient
intens
care
unit
pvalu
calcul
use
mannwhitney
test
quantit
valu
use
fisherexact
test
qualit
one
plasma
concentr
fgml
determin
singl
molecul
array
simoa
bcd
crp
concentr
measur
use
multiplex
assay
ella
platform
e
viral
load
repres
cycl
threshold
rtqpcr
use
assay
design
pasteur
institut
pari
ifninterferon
interleukin
crp
creactiv
protein
interferon
protein
ifn
score
transcriptionn
signatur
defin
interferonstimul
gene
isg
quantifi
use
nanostr
technolog
obtain
paxgen
tube
patient
bd
normal
valu
healthi
volunt
indic
grey
area
vertic
bar
indic
median
delay
symptom
onset
icu
admiss
concentr
quantifi
patient
lack
materi
